Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
26 June 2018
E-001096/2018
Answer given by First Vice-President Timmermans on behalf of the Commission

Healthcare is a sector exposed to specific corruption risks(1). As noted in the Commission’s reply to E-000040/2017, the Commission has prioritised sharing of good practices in fighting corruption in this sector in its EU anti-corruption experience sharing programme and supported relevant work at the European Partners against Corruption (EPAC) — European contact-point network against corruption (EACN).

The Commission has also recently published an updated study of corruption in the healthcare sector(2) that includes, inter alia, an analysis of improper marketing practices and corruption in the procurement of medical devices and pharmaceutical products as well informal payments in healthcare.

In addition, the Commission has encouraged Member States to take steps to address the issue of corruption also in healthcare in the framework of the European semester of economic governance.

(1)In 2017, 39% of companies active in the healthcare and pharmaceutical sectors are citing corruption as a problem for them when doing business (Flash Eurobarometer 457: Businesses’ attitudes towards corruption in the EU).
(2)https://ec.europa.eu/home-affairs/sites/homeaffairs/files/20170928_study_on_healthcare_corruption_en.pdf

Last updated: 26 June 2018Legal notice